Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

ABSTRACT:

Background

Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor α (ERα) positive breast cancer patients that derive benefit from tamoxifen is not well established. We tested the predictive value of these markers for tamoxifen benefit in ERα positive postmenopausal breast cancer patients.

Methods

We collected primary tumor blocks from 563 ERα positive patients who had been randomized between tamoxifen (1 to 3 years) vs. no adjuvant therapy (IKA trial) with a median follow-up of 7.8 years. Mitotic count, Ki67 and Cyclin D1 protein expression wer

SUBMITTER: Beelen K 

PROVIDER: S-EPMC6057037 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature